Ironwood Pharmaceuticals Reports $300M Adjusted EBITDA Guidance
Ironwood Pharmaceuticals (NASDAQ:IRWD) on Feb. 25 announced fiscal 2026 adjusted EBITDA guidance of at least $300 million and reaffirmed its 2026 outlook, citing improving LINZESS dynamics. On Feb. 26 Citizens analyst Jason Butler maintained an Outperform rating and raised the price target to $10. The company plans Phase 3 STARS-2 site initiations in Q2 and continues development of apraglutide for SBS-IF.
Key Points
- 1Announces fiscal 2026 adjusted EBITDA guidance of at least $300 million, reaffirming company outlook
- 2Highlights easing LINZESS headwinds, improving cash flow to support debt reduction and growth
- 3Plans Phase 3 STARS-2 trial initiation in Q2 and advances apraglutide development for SBS-IF
Scoring Rationale
Same-day company guidance and analyst confirmation provide credible, actionable investor information. Score reflects moderate novelty and company-level scope, strong credibility from official guidance, but limited broader industry impact and non-technical relevance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
